The continuing operations of GeneDx, excluding revenues and costs from exited business activities, are expected to: Generate revenues between $205-220 million for full year 2023; Expand gross margin profile in 2023 and beyond; Use net $95-110 million of cash in 2023 for continuing operations. Inclusive of servicing obligations of the exited business activities, the Company’s cash burn in 2023 is expected to be in the range of $130-145 million and; Turn profitable in 2025.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SMFR:
- Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Myriad Genetics appoints Glenn Farrell as CMO
- Sema4 Holdings downgraded to Neutral from Buy at Goldman Sachs
- Sema4 announces results of new study on mitochondrial diseases in newborns
- New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
